The facts
Xaira Therapeutics at a glance.
Read Oct 20, 2026. Valuations and amounts are copied as each source states them; a figure that is only reported (talks, or people familiar with the deal) is labeled as reported.
- Kind of company
- Drug discovery and biologyAI that designs drugs, proteins and antibodies.
- Based in
- South San Francisco, United States
- Founded
- 2024Bloomberg News, Apr 23, 2024
- Last closed-round valuation
- No valuation reported
- What it has shipped
- Research only so far
Founders
- Marc Tessier-Lavigne: CEO (named as CEO, not founder); former president of Stanford and Rockefeller universities; former Genentech research SVP; Denali Therapeutics co-founder (Bloomberg News, Apr 23, 2024)
Revealed its antibody design platform and first pipeline programs (company post, no peer-reviewed paper or preprint cited). Oct 2, 2026
Xaira Therapeutics (company), Oct 2, 2026
What it has built
Shipped, or not yet.
“Research only so far” is what our search found: something the public can use or buy, a model or API, research only, or nothing public.
1 round
Funding, as reported.
Every round we found, with the amount, valuation and investors as the source states them.
| When | Round | Amount | Valuation | Investors named | Source |
|---|---|---|---|---|---|
| Apr 23, 2024 | Launch financing (capital commitments) | $1 billion | Not stated | ARCH Venture Partners (incubator), Foresite Labs (incubator), Sequoia Capital, Lightspeed Venture Partners, F-Prime, NEA, Lux Capital, Menlo Ventures, Two Sigma Ventures, Parker Institute for Cancer Immunotherapy | Bloomberg News |
Our note
Worth knowing.
Our note: No clinical trial registry entry or peer-reviewed paper by Xaira was found; programs are preclinical (XA-4 'has entered lead optimization'). Its homepage quote is cut off at the word 'power' (it continues to name AI). Later funding was not verified.
More drug discovery and biology